

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)



(10) International Publication Number
WO 2020/168143 A1

(51) International Patent Classification:

C07D 217/06 (2006.01) A61K 31/427 (2006.01)
C07D 403/12 (2006.01) A61P 3/06 (2006.01)
C07D 413/12 (2006.01) A61P 13/00 (2006.01)
C07D 413/14 (2006.01) A61P 35/00 (2006.01)
C07D 417/12 (2006.01)

(21) International Application Number:

PCT/US2020/018203

(22) International Filing Date:

14 February 2020 (14.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/806,066 15 February 2019 (15.02.2019) US

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY

[US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(72) Inventors: WACKER, Dean A.; c/o Bristol-Myers Squibb

Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). NARA, Susheel Jethanand; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore, Karnataka 560 099 (IN). CHERUKU, Srinivas; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore, Karnataka 560 099 (IN). SARKUNAM, Kandhasamy; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore, Karnataka 560 099 (IN). JAIPURI, Firoz Ali; Flat No. 1702, Hibiscus A Wing, Salarpuria Sattva Greenage, Hosur Main Road, Bommanahalli, Bengaluru, Karnataka 560 068 (IN). THANGAVEL, Soodamani; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2 & 3, Bommasandra Indus-

trial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore, Karnataka 560 099 (IN). NARAYAN, Rishikesh; Goa Engineering College (GEC) Campus, Farmagudi Ponda, Goa 403 401 (IN). BANDREDDY, Subba Reddy; Flat No. 207 SLV Pride Apts, Chikkathogur Main Road, Pragathi Nagar, Bangalore, Karnataka 560 100 (IN). JOGI, Srinivas; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore, Karnataka 560 099 (IN). KATHI, Pavan Kalyan; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore, Karnataka 560 099 (IN).

(74) Agent: GREENBLATT, Gary D. et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).


(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS



(I)

(57) Abstract: Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*